

Safety of the second generation antipsychotics during pregnancy (Second generation antipsychotics and pregnancy)

First published: 23/09/2013

Last updated: 23/04/2024

Study

Finalised

Administrative details

EU PAS number

EUPAS4799

Study ID

42972

DARWIN EU® study

No

Study countries

 Finland

Study description

Second generation antipsychotics have largely replaced first generation antipsychotics but little is known about their safety during pregnancy. This is a population based study based on national register data in Finland. Data from the National Birth Register, the Register of Congenital Malformations, and the Drug Prescription Register have been linked through years 1996-2012 in the Drugs and Pregnancy project, and data in this study are extracted from the Drugs and Pregnancy project database. The data include all births (live and still births), pregnancy terminations due to major congenital anomaly, and information on drug purchases during pregnancy and 3 months before pregnancy. There are appr. 55,000-60,000 births per year in Finland, and we expect to have a baseline study population with appr. 1 mil. pregnancies. Appr. 0.2-0.6% of pregnant women during the study period used antipsychotics and we expect to include appr.2,000 pregnancies exposed to second generation antipsychotics. The primary aims of the study are i.) to assess the risk of major congenital anomalies after first trimester exposure to second generation antipsychotics and ii.) to investigate the prevalence of other perinatal outcomes, including large for gestational age, preterm birth, low birth weight, and perinatal mortality after continuous exposure. The exposed group is compared i) to women and their offspring exposed to first generation antipsychotics during the period of three months prior to pregnancy until the end of pregnancy (to control for maternal illness), and ii) to unexposed women. Logistic regression is used to evaluate associations between exposure and outcome, and covariates to be considered include year of birth, mother's age, parity, tobacco use, prepregnancy diabetes, use of other psychiatric drugs and use of drugs classified as potentially harmful. The results will provide important information on the safety of second generation antipsychotics during pregnancy.


Study status

Finalised

Research institutions and networks

Institutions

Finnish Institute for Health and Welfare (THL)

 Finland

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Educational Institution

Laboratory/Research/Testing facility

Contact details

Study institution contact

Heli Malm heli.malm@hus.fi

Study contact

heli.malm@hus.fi

Primary lead investigator

Heli Malm

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 01/01/2012

Actual: 01/01/2012

Study start date

Planned: 15/05/2014

Actual: 15/05/2014

Data analysis start date

Planned: 15/09/2014

Actual: 01/09/2016

Date of interim report, if expected

Planned: 31/10/2018

Date of final study report

Planned: 01/09/2019

Actual: 03/11/2019

Sources of funding

- Other

More details on funding

Finnish Medicines Agency

Study protocol

[NEW_antipsychotics_HM.pdf](#) (88.33 KB)

[NEW_antipsychotics_HM__09052014.pdf](#) (95.42 KB)

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Human medicinal product

Disease /health condition

Study type:

Non-interventional study

Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness

Safety study (incl. comparative)

Data collection methods:

Secondary use of data

Main study objective:

To assess pregnancy-related risks associated with the use of second generation antipsychotics. These include major congenital anomalies and perinatal outcomes including preterm birth, birth weight, perinatal death etc.

Study Design

Non-interventional study design

Cohort

Population studied

Short description of the study population

Exposed cohort:

The definition of exposure includes pregnancies where the woman has purchased second generation antipsychotics (4th level ATC code N05AE, N05AH, N05AL, N05AX) at any time during pregnancy and/ or one month before pregnancy. Major congenital anomalies will be analyzed in the cohort with purchase(s) during one month prior to pregnancy or during the first trimester

The two unexposed reference groups consist of:

- 1. All pregnant women and their offspring not exposed to second generation antipsychotics during pregnancy and three months before pregnancy, but exposed to first generation antipsychotics (ATC codes N05AA, N05AB, N05AC, N05AD, N05AF) at any time during the period of three months before pregnancy until the end of pregnancy
 - 2. Pregnant women and their offspring unexposed to second generation antipsychotics during the period of three months prior to pregnancy until the end of pregnancy
-

Age groups

- Preterm newborn infants (0 - 27 days)
 - Term newborn infants (0 - 27 days)
 - Adolescents (12 to < 18 years)
 - Adults (18 to < 46 years)
-

Special population of interest

Pregnant women

Estimated number of subjects

10000

Study design details

Outcomes

Major congenital anomalies, perinatal outcomes including preterm birth >37 weeks and very preterm birth (<32 weeks), low birth weight (<2500g) and very low birth weight (<1500g), perinatal death, mode of delivery, neonatal outcome (Apgar score, hypoxia, need for treatment in neonatal care unit, etc).

Data analysis plan

All data are anonymized and coded prior to statistical analysis. The prevalence of specific outcomes is compared between exposed and unexposed pregnant women and their offspring. Univariate analyses are used to study demographic differences between the study cohorts, and logistic regression to assess the association between new generation antipsychotic use during pregnancy and major congenital anomalies (MCA) and perinatal outcomes. With an estimated of 2,000 exposed births and fetuses from elective terminations of pregnancy due to fetal anomaly, the study has a 98.3% power to detect a 60% relative increase (1.8% absolute increase) in the prevalence of MCAs presuming a

baseline prevalence of 3% in the control cohort ($\alpha = 0.05$, two-sided), and for perinatal complications that have a prevalence of 6% (as preterm birth) we have a 98.3% power to detect a 40% relative risk increase (2.4% absolute risk increase).

Documents

Study results

[ABSTRACT_121019.pdf](#) (2.99 KB)

[SGA_malformations_Ellfolk et al..pdf](#) (352.71 KB)

Study publications

[Ellfolk M, Leinonen MK, Gissler M, Lahesmaa-Korpinen AM, Saastamoinen L, Nurmin...](#)

[Ellfolk M, Leinonen MK, Gissler M, Kiuru-Kuhlefelt S, Saastamoinen L, Malm H. S...](#)

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

This study has been awarded the ENCePP seal

Conflicts of interest of investigators

[CI_M-LN.pdf](#) (1.39 MB)

Composition of steering group and observers

[Specification of steering group.pdf](#) (17.06 KB)

Data sources

Data source(s), other

Drugs and Pregnancy Finland

Data sources (types)

[Administrative healthcare records \(e.g., claims\)](#)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No